Open AccessExpression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung
Author(s) -
William Sterlacci,
Michael Fiegl,
Raoul A. Droeser,
Alexandar Tzankov
Publication year - 2016
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000444804
Subject(s) - medicine , lung cancer , oncology , immunohistochemistry , adenocarcinoma , pd l1 , biomarker , clinical trial , lung , immunotherapy , cancer , biology , biochemistry
In light of various trials showing impressive response rates when treating non-small cell lung cancer (NSCLC) patients with anti PD-1/PD-L1 antibodies, the currently equivocal role of PD-L1 expression in NSCLC is in need of further clarification.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom